Vantage Point Financial’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.08M Sell
1,173
-41
-3% -$41.6K 0.38% 51
2025
Q4
$1.3M Buy
1,214
+148
+14% +$142K 0.47% 48
2025
Q3
$813K Sell
1,066
-66
-6% -$49.1K 0.32% 63
2025
Q2
$882K Sell
1,132
-101
-8% -$78.5K 0.39% 54
2025
Q1
$1.02M Buy
1,233
+152
+14% +$126K 0.51% 44
2024
Q4
$835K Buy
+1,081
New +$895K 0.45% 47

Other funds holding LLY

Vantage Point Financial's LLY Position: Q1 2026 in Review

Vantage Point Financial reduced its Eli Lilly (LLY) stake by 3.4% in Q1 2026, selling an estimated $41.6K and leaving 1,173 shares worth $1.08M. The position accounts for 0.38% of the portfolio, ranked #51.

Vantage Point Financial first reported a position in LLY in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.3M in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Vantage Point Financial held 1,173 shares of Eli Lilly worth $1.08M as of Q1 2026.
  • Vantage Point Financial sold 41 Eli Lilly shares in Q1 2026, an estimated $41.6K.
  • Eli Lilly made up 0.38% of Vantage Point Financial's portfolio in Q1 2026, its #51 holding.
  • Vantage Point Financial first reported a position in Eli Lilly in Q4 2024 and has held it in 6 quarters since.
  • Vantage Point Financial's Eli Lilly position peaked at $1.3M in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Vantage Point Financial's 13F filing for Q1 2026, filed 4 May 2026.